High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 2, 2011, Pages 213-220

  Bordignon, V ^a   Bultrini, S ^a   Prignano, G ^a   Sperduti, I ^a   Piperno, G ^b   Bonifati, C ^a   Filippetti, M ^b   Toma, L ^a   Latini, A ^a   Di Cecio, M ^b   Giuliani, A ^a   Vocaturo, A ^b   Trento, E ^a   D'Agosto, G ^a   Francesconi, F ^a   Cataldo, A ^b   Vento, A ^a   Cilenti, V ^b   Berardesca, E ^a   Ameglio, F ^a   Cordiali Fei, Paola ^a   Ensoli, F ^a   more..

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chronic lung disease; Health care workers; HIV; IGRA; Immigrants; LTBI; Lung cancer; Psoriasis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BCG VACCINE; GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; FEMALE; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMMIGRANT; IMMUNE RESPONSE; INTERSTITIAL LUNG DISEASE; LATENT TUBERCULOSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PSORIASIS; PSORIASIS VULGARIS; ADENOCARCINOMA; BIOSYNTHESIS; DRUG ANTAGONISM; EARLY DIAGNOSIS; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ITALY; LUNG; LUNG TUMOR; MICROBIOLOGY; MIDDLE AGED; MIGRATION; PHYSIOLOGY; SECRETION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MYCOBACTERIUM TUBERCULOSIS;

ADENOCARCINOMA; ADULT; ANTIBODIES; AUTOIMMUNE DISEASES; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; EMIGRANTS AND IMMIGRANTS; FEMALE; HEALTH PERSONNEL; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; ITALY; LATENT TUBERCULOSIS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80052945606     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. World Health Organization. Global tuberculosis database. Available at: http://www.who.int./tb/country/en/index.html.
2. Rieder HL. Estimating the prevalence of tuberculosis infection in the United States population. Am J Respir Crit Care Med 2008; 178:651.
3. Centers for Disease Control and Prevention (CDC). Trends in tuberculosis e United States, 2004. Morb Mortal Wkly Rep 2005; 54:245-9.
4. Scotto G, Fornabaio C, Prato R, Saracino A, Tartaglia A, Di Tullio R, Carbonara S, Angarano G. Tuberculosis and immigrants: a SIMIT (Italian Society of Infectious Diseases) clinical, epidemiological multicentric research investigation. Italian Study Group for Infectious Diseases in Immigrants. New Microbiol 2009; 32:39-47.
5. Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001; 39:2213-8. (Pubitemid 32531483)
6. Kherad O, Herrmann FR, Zellweger JP, Rochat T, Janssens JP. Clinical presentation, demographics and outcome of Tuberculosis (TB) in low incidence area: a 4 year study in Geneva, Switzerland. BMC Infectious Diseases 2009; 9:217.
7. Bonaccorsi G, Lorini C, Mannelli D, Postiglione M, Boddi V, Comodo N. The prevalence of latent tuberculosis infection in social marginal groups. An experience conducted in Tuscany. Ig Sanita Pubbl 2007; 63:561-75.
8. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367:938-40.
9. Faggiano F, Vigna-Taglianti FD, Versino E, Salamina G, Bugiani M. Tuberculosis incidence in Turin, Italy, 1973-1999. Int J Tuberc Lung Dis 2004; 8:171-9. (Pubitemid 38622924)
10. European Centre for Disease Prevention and Control/WHO Regional Office for Europe: Tuberculosis surveillance in Europe 2008. Stockholm, European Centre for Disease Prevention and Control 2010.
11. National Tuberculosis Controllers Association. Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005; 54:1-47.
12. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19:765-75.
13. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293:2767-75. (Pubitemid 40965089)
14. Ardies CM. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther 2003; 2:238-46. (Pubitemid 37127930)
15. Nalbandian A, Yan BS, Pichugin A, Bronson RT, Kramnik I. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene 2009; 28:1928-38.
16. Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QC, Zhou BS. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer 2009; 125:2936-44.
17. Gottlieb A, Korman NJ, Gordon KB. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58:851-64. (Pubitemid 351509657)
18. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
19. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008; 59:363-80.
20. Yoo WH. Multiple organ tuberculosis of lung, pleura and peritoneum in ankylosing spondylitis during adalimumab therapy. Reumathol Int 2010; (Epub ahead of print).
21. Cardona J. New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets 2006; 6:27-39.
22. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4:761-76.
23. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007; 131:1898-906. (Pubitemid 46981652)
24. De Portu S, Del Giglio M, Altomare G, et al. Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatol Ther 2010; 23:S7-13.
25. Ramsay B, Lawrence C. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991; 124:565-70.
26. Global tuberculosis control. Epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.393. http://www.who.int/tb/publications/global- report/2009/pdf/full-report.pdf.
27. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005. MMWR Recomm Rep 2005; 1-141.
28. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese health care workers. Infect Control Hosp Epidemiol 2006; 27:442-8. (Pubitemid 43835524)
29. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-59. (Pubitemid 41400849)
30. Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198:1590-8.